Milatuzumab

Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.

The drug is the first anti-CD74 antibody that has entered into human testing and is currently being studied for the treatment of multiple myeloma. Milatuzumab has received orphan drug designation from the Food and Drug Administration in the United States for the treatment of multiple myeloma and chronic lymphocytic leukemia.

单词	Milatuzumab
释义	Milatuzumab 英语百科 Milatuzumab Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. The drug is the first anti-CD74 antibody that has entered into human testing and is currently being studied for the treatment of multiple myeloma. Milatuzumab has received orphan drug designation from the Food and Drug Administration in the United States for the treatment of multiple myeloma and chronic lymphocytic leukemia.
随便看	HTS HTSAB HTSC HTSCA HT selector HTSG HTSH HTSH EIA HTSH RIAbead Hts.,hts. HTSI HTSIM HTST HT stabilizer ht steamer HTST method HTSUP HT Supplement H.T.supply .htt HTTA HTT htteroinoculation htteroplasia HT testing transformer